October 30, 2023 Non Regulatory InDex Pharmaceuticals Holding AB (publ) announces Nomination Committee for the 2024 Annual General Meeting Read more
October 30, 2023 Non Regulatory InDex Pharmaceuticals Holding AB (publ) offentliggör valberedning inför årsstämman 2024 Read more
October 20, 2023 Non Regulatory InDex Pharmaceuticals has been granted a new patent for cobitolimod in South Korea Read more
October 20, 2023 Non Regulatory InDex Pharmaceuticals har beviljats ett nytt patent för cobitolimod i Sydkorea Read more
October 11, 2023 Non Regulatory InDex Pharmaceuticals announces that all patients needed for the cobitolimod dose selection milestone have completed Induction Study 1 of the phase III program CONCLUDE Read more
October 11, 2023 Non Regulatory InDex Pharmaceuticals meddelar att alla patienter som krävs för att nå milstolpen för dosvalet av cobitolimod har slutfört Induktionsstudie 1 av fas III-programmet CONCLUDE Read more
October 5, 2023 Non Regulatory InDex Pharmaceuticals deltar vid United European Gastroenterology Week 2023 Read more
August 22, 2023 Non Regulatory ”Positive results from PK study with cobitolimod” selected as one of the best abstracts for poster presentation at UEGW Read more
August 22, 2023 Non Regulatory ”Positiva resultat från PK-studie med cobitolimod” utsedd till en av de bästa abstrakten för posterpresentation vid UEGW Read more
May 31, 2023 Non Regulatory InDex Pharmaceuticals investeraruppdatering 1 juni kl. 15:00 CET Read more
May 31, 2023 Non Regulatory InDex Pharmaceuticals investeraruppdatering 1 juni kl. 15:00 CET Read more
April 26, 2023 Non Regulatory Welcome to an InDex Pharmaceuticals business update presentation in Stockholm on May 9, from 13:00 to 15.30 CET Read more
April 26, 2023 Non Regulatory Välkommen till InDex Pharmaceuticals Business Update-presentation i Stockholm den 9 maj, kl 13:00 till 15.30 CET Read more
March 15, 2023 Non Regulatory InDex Pharmaceuticals announces positive results from a pharmacokinetic (PK) study with cobitolimod Read more
March 15, 2023 Non Regulatory InDex Pharmaceuticals meddelar positiva resultat från en farmakokinetikstudie (PK-studie) med cobitolimod Read more
February 14, 2023 Non Regulatory InDex Pharmaceuticals provides complementary information on the phase III program CONCLUDE with cobitolimod Read more
February 14, 2023 Non Regulatory InDex Pharmaceuticals tillhandahåller kompletterande information om fas III-programmet CONCLUDE med cobitolimod Read more